Computational investigations of the binding mechanism of novel benzophenone imine inhibitors for the treatment of breast cancer.
Ontology highlight
ABSTRACT: 4-Hydroxytamoxifen (4-OHT), the most common hormone used for the treatment of breast cancer, is a selective estrogen receptor modulator (SERM) inhibitor that acts as an antagonist in breast tissue and a partial agonist in the endometrium. However, the detailed molecular mechanism of 4-OHT structure modification has not been well investigated to date. Herein, molecular docking, molecular dynamics simulations and free energy calculations were performed to explore the mechanisms of the molecular interactions between newly designed benzophenone imines (BIs) and the three forms apo, antagonist and agonist of the human estrogen receptor hERα. The proposed inhibitors were designed by replacing the triarylethylene estrogenic scaffold found in 4-OHT with Schiff base triarylimine derivatives. The an
SUBMITTER: Shtaiwi A
PROVIDER: S-EPMC9082406 | biostudies-literature | 2019 Oct
REPOSITORIES: biostudies-literature
ACCESS DATA